Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study
- Conditions
- ewly diagnosed Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2019-001645-41-SE
- Lead Sponsor
- Memorial Sloan Kettering Cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 462
•Newly diagnosed patients with histologically confirmed MM based on the following criteria:
-Clonal plasma cells in the bone marrow
-Measurable disease within the past 4 weeks defined by any one of the following: - Serum monoclonal protein = 1.0 g/dL
Urine monoclonal protein >200 mg/24 hour
Involved serum immunoglobulin free light chain > 10 mg/dL AND abnormal kappa/lambda ratio
•Evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following:
-Hypercalcemia: serum calcium >0.25 mmol/L (> 1 mg/dL) above upper limit of normal or = 2.75 mmol/L (11 mg/dL)
-Anemia: hemoglobin value <10 g/dL or > 2 g/dL below lower limit of normal
-Bone disease: = 1 lytic lesions on skeletal X-ray, CT, or PET-CT. For patients with 1 lytic lesion, bone marrow should demonstrate =10% clonal plasma cells
-Clonal bone marrow plasma cell percentage =60%
Involved/un-involved serum free light chain ratio =100 and involved free light chain >100 mg/L.
- > 1 focal lesion on magnetic resonance imaging study (lesion must be >5 mm) in size
•Creatinine Clearance = 60 ml/min. CrCl can be measured or estimated using Cockcroft-Gault method, MDRD, or CKD-EPI formulae
•Age = 18 years at the time of signing the informed consent documentation. Age limit of = 75 years for Cohort 3 patients.
•Eastern Cooperative Oncology Group (ECOG) performance status 0-2
•Absolute neutrophil count (ANC) = 1.0 K/uL, hemoglobin = 8 g/dL, and platelet count = 75 K/uL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator. Transfusions and growth factors are permissible.
•Adequate hepatic function, with bilirubin < 1.5 x the ULN, and AST and ALT < 3.0 x ULN.
•All study participants must be able to tolerate one of the following thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin (coumadin) or alternative anti-coagulant.
•All study participants must be registered into the mandatory eREMS® program, and be willing and able to comply with the requirements of REMS®.
•Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test within 10 – 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 231
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 231
-Patients receiving >1 cycle of prior treatment or concurrent systemic treatment for multiple myeloma
-Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted
-Bisphosphonates are permitted
-Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted
-Prior treatment with radiotherapy is permitted
-Prior Multiple Myeloma treatment for smoldering myeloma such as IMIDs and mABs is permitted with a washout period of 2weeks from last dose. Smoldering patients previously treated with carfilzomib are excluded.
-Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 2 weeks from last dose (on a trial or outside a trial) are eligible
•Plasma cell leukemia
•POEMS syndrome
•Amyloidosis
•Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal (note that FEV1 testing is required for subjects suspected of having chronic obstructive pulmonary disease and subjects must be excluded if FEV1 <50% of predicted normal).
•Pregnant or lactating females. Because there is a potential risk for adverse events nursing infants secondary to treatment of the mother with carfilzomib in combination with lenalidomide. These potential risks may also apply to other agents used in this study.
•Uncontrolled hypertension or diabetes
•Active hepatitis B or C infection
•Subject is:
-Seropositive for human immunodeficiency virus (HIV)
-Seropositive for hepatitis B
-Seropositive for hepatitis C
•Has significant cardiovascular disease with NYHA Class III or IV symptoms, EF<40% or hypertrophic cardiomyopathy, or restrictive cardiomyopathy, or myocardial infarction within 6 months prior to enrollment, or unstable angina, or unstable arrhythmia as determined by history and physical examination. Echocardiogram will be performed during screening evaluation.
•Pulmonary hypertension
•Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption of oral agents
•Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness/social situations that would compromise compliance with study requirements
•Significant neuropathy =Grade 3 or Grade 2 neuropathy with pain at baseline
•Contraindication to any concomitant medication, including antivirals or anticoagulation.
•Major surgery within 3 weeks prior to first dose
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method